Boehringer Ingelheim appoints Abdallah Hamed to lead SAGEA Region

SAUDI ARABIA –Boehringer Ingelheim, a global leader in biopharmaceuticals, has appointed of Abdallah Hamed as the General Manager and Head of Human Pharma for Saudi Arabia, the Gulf, and East Africa (SAGEA), effective October 1, 2024.  

In his new role, Hamed will lead strategic growth efforts across several critical healthcare sectors, including stroke, cardio-renal metabolic conditions, idiopathic pulmonary fibrosis, and rare diseases like generalized pustular psoriasis.  

His focus will be on advancing the company’s regional priorities, fostering innovation, and expanding market reach to deliver Boehringer Ingelheim’s leading healthcare solutions. 

 In addition to driving business objectives, Hamed aims to deepen the company’s partnerships with regional governments and key healthcare stakeholders, ensuring that patients continue to benefit from Boehringer Ingelheim’s diverse range of medications and treatments.  

His appointment underscores Boehringer Ingelheim’s commitment to strengthening its ties with local stakeholders and advancing patient access across the SAGEA region. 

 Hamed’s career spans over two decades in the pharmaceutical industry, where he has held significant leadership positions throughout the Middle East, including in Oman, the UAE, Bahrain, and Saudi Arabia.  

His experience has been marked by successful initiatives that have propelled business growth across these markets.  

Hamed holds a bachelor’s degree in pharmacy from the Applied Science University in Jordan and brings a comprehensive understanding of market dynamics, alongside proven expertise in sales, market access, and managing business units. 

 Derek O’Leary, Regional Managing Director for India, the Middle East, Turkey, and Africa (IMETA) at Boehringer Ingelheim, expressed his enthusiasm about Hamed’s leadership.  

He highlighted Hamed’s extensive industry experience and dedication to enhancing healthcare, emphasizing that these qualities will significantly strengthen Boehringer Ingelheim’s presence and impact in the SAGEA region. 

 O’Leary added that he is confident Hamed’s guidance will drive continued innovation and patient-centered value, fortifying the company’s partnerships with key healthcare players. 

Reflecting on his new position, Hamed noted the rapid evolution of the regional pharmaceutical landscape over the past 20 years, shaped by growing demand for innovative and personalized treatments, advances in medical technology, and a stronger focus on patient-centered care.  

He expressed excitement at the opportunity to influence the future of this dynamic market, leveraging Boehringer Ingelheim’s global expertise and resources.  

Hamed emphasized the importance of building on the company’s existing relationships, fostering new collaborations, and continuing to drive innovation.  

His vision includes addressing local healthcare challenges to deliver sustainable solutions that positively impact both human and animal health across the region. 

 Boehringer Ingelheim has been committed to the Middle East since the 1970s, emphasizing innovation as a core principle for over 50 years. 

A significant portion of its operations in Saudi Arabia is dedicated to animal health, particularly focusing on diseases affecting poultry, livestock, and companion animals, further underscoring its comprehensive approach to healthcare in the Kingdom. 

Sign up to receive our email newsletters with the latest news updates and  insights from Africa and the World HERE